ANGPTL3 inhibitor monoclonal antibody
Evinacumab
Brand names: Evkeeza
Adult dose
Dose: 15 mg/kg IV every 4 weeks
Route: IV
Frequency: q4w
Clinical pearls
- Homozygous familial hypercholesterolaemia in adults and children ≥5 yr; specialist lipid clinic
Contraindications
- Hypersensitivity
Side effects
- Infusion-related reactions
- Headache
- Influenza-like illness
- Nasopharyngitis
Interactions
- Avoid live vaccines
Monitoring
- Lipids
- Pregnancy testing
Reference: BNF; NICE TA814; SmPC; https://bnf.nice.org.uk/drugs/evinacumab/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Pathways
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines